MET knockdown sensitized resistant cells to EGF and reduced their anchorage-independent growth and migration, while combination therapy with a MET inhibitor and cetuximab showed additive effects, suggesting a potential therapeutic strategy for MET-driven resistance in lung cancer. This evidence concerns the gene MET and lung cancer.